PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933311
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933311
Mucopolysaccharidosis Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of mucopolysaccharidosis (MPS) treatment Market
The global mucopolysaccharidosis (MPS) treatment market is projected to witness significant growth over the coming decade. In 2025, the market was valued at USD 3.96 billion, expected to grow to USD 4.37 billion in 2026 and reach USD 9.74 billion by 2034, reflecting a CAGR of 10.54% from 2026-2034. North America dominated the market with a 52.10% share in 2025, primarily driven by high diagnosis rates, strong clinical trial activity, and favorable reimbursement policies.
MPS is a group of rare metabolic disorders caused by deficiencies in lysosomal enzymes, leading to abnormal accumulation of glycosaminoglycans (GAGs) in cells. This results in severe symptoms, including neurological complications, organ dysfunction, and growth abnormalities. The growing need for advanced therapeutics and unmet clinical needs has propelled market growth globally.
Market Drivers
The MPS treatment market is primarily driven by the need for advanced therapeutics due to unmet clinical needs and better treatment outcomes. Current treatments, such as enzyme replacement therapies (ERTs) like Elaprase for Hunter syndrome and Vimizim (elosulfase alfa) for Morquio syndrome, are often prohibitively expensive, limiting access in developing countries. Additionally, existing therapies cannot cross the blood-brain barrier, leaving neurological symptoms largely untreated.
Increasing R&D initiatives by biopharmaceutical companies like ArmaGen, REGENXBIO, and Denali Therapeutics are focusing on developing advanced therapies, including gene therapies and hematopoietic stem cell transplantation (HSCT), to address the full spectrum of MPS symptoms. This pipeline expansion is expected to drive market growth during the forecast period.
Market Restraints
The market faces restraints due to high therapeutic costs, poor diagnosis rates, and limited access in emerging countries. ERTs are extremely expensive, with annual treatment costs reaching six figures, making them unaffordable for many patients. Diagnostic delays, lack of awareness, and insufficient government reimbursement further restrict market expansion in developing regions.
Market Trends
A key trend is the increasing focus on rare and orphan disease therapies. MPS, as an orphan disorder, attracts significant attention from biopharmaceutical companies aiming to develop blockbuster treatments in niche markets. Clinical trials for multiple MPS types are increasing, reflecting growing investment in rare disease drug development.
Additionally, advancements in gene therapy and stem cell treatments represent a shift from conventional ERTs toward potentially curative therapies, increasing the attractiveness of the market to investors and healthcare providers.
Segmentation Analysis
By Treatment Type:
- Enzyme Replacement Therapy (ERT) dominates the market, accounting for 93.89% of the market in 2026, due to its established efficacy in treating lysosomal storage disorders.
- Other treatments, including gene therapy and HSCT, are expected to grow at higher CAGR during the forecast period as more pipeline candidates advance through clinical trials.
By Disease Type:
- MPS II (Hunter Syndrome) is projected to dominate with 24.25% market share in 2026, owing to key products like Elaprase and Hunterase.
- Other types, including MPS I, IV A, VI, and VII (Sly syndrome), are expected to grow steadily, supported by newly approved therapeutics such as MEPSEVII (vestronidase alfa-vjbk).
By Route of Administration:
- Intravenous (IV) administration dominates with 98.16% of revenue in 2026, as most approved therapies, including Elaprase, are delivered intravenously.
- Intracerebroventricular (ICV) administration is limited but gaining attention with products like Hunterase.
By End-User:
- Hospitals dominate the segment with 61.55% share in 2026, given the need for trained professionals to administer IV therapies safely.
- Specialty clinics and other facilities are expanding in developed regions, driven by patient demand for specialized care.
Regional Analysis
North America: Market size of USD 2.06 billion in 2025, projected to reach USD 2.13 billion in 2026, driven by high awareness, reimbursement, and clinical trials.
Europe: Second-largest market with strong product presence; projected to grow at CAGR of 9.9%, with UK reaching USD 0.18 billion and Germany USD 0.27 billion by 2026.
Asia-Pacific: Expected fastest growth due to strong patient base and upcoming therapeutic launches; Japan market USD 333.9 million in 2025, projected to reach USD 0.37 billion in 2026, China market expected to reach USD 0.27 billion, and India USD 0.13 billion by 2026.
Rest of World: Latin America and Middle East & Africa are emerging markets, supported by growing healthcare infrastructure and government initiatives.
Competitive Landscape
The MPS treatment market is semi-consolidated, led by Shire (Takeda Pharmaceutical Company Limited) with Elaprase, and BioMarin with ALDURAZYME, VIMIZIM, and NAGLAZYME. Clinical-stage players like ArmaGen, REGENXBIO, Sangamo Therapeutics, and Denali Therapeutics are developing pipeline candidates to capture future market share. Key developments include FDA Fast Track designations for gene therapy candidates like LYS-SAF302 (Lysogene) and ABO-101 (Abeona Therapeutics).
Conclusion
The global mucopolysaccharidosis treatment market is projected to grow from USD 3.96 billion in 2025 to USD 9.74 billion by 2034, at a CAGR of 10.54%. Market growth is primarily driven by the unmet need for advanced therapeutics, increasing R&D investment in rare disease therapies, and emerging innovative treatments including gene therapy and stem cell interventions. While high costs and limited access in emerging countries remain challenges, expanding clinical pipelines, technological advancements, and increasing awareness are set to fuel sustainable growth in the MPS treatment market across all regions.
Segmentation By Treatment
- Enzyme Replacement Therapy (ERT)
- Others
By Disease Type
- Mucopolysaccharidosis Type I
- Mucopolysaccharidosis Type II
- Mucopolysaccharidosis Type IV A
- Mucopolysaccharidosis Type VI
- Others
By Route of Administration
- Intravenous
- Intracerebroventricular (ICV)
By End User
- Hospitals
- Specialty Clinics
- Others
By Geography
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
- Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
- Rest of the World
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Prevalence of Key Mucopolysaccharidosis Types - by key regions (2025)
- 4.2. Pipeline Analysis
- 4.3. Key Industry Developments
- 4.4. Regulatory Scenario- by Key Regions
- 4.5. Overview of Emerging Treatments for Mucopolysaccharidosis
- 4.6. Reimbursement Scenario - by Key Regions
5. Global Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast - By Treatment
- 5.2.1. Enzyme Replacement Therapy (ERT)
- 5.2.2. Others
- 5.3. Market Analysis, Insights and Forecast - By Disease Type
- 5.3.1. Mucopolysaccharidosis Type I
- 5.3.2. Mucopolysaccharidosis Type II
- 5.3.3. Mucopolysaccharidosis Type IV A
- 5.3.4. Mucopolysaccharidosis Type VI
- 5.3.5. Others
- 5.4. Market Analysis, Insights and Forecast - By Route of Administration
- 5.4.1. Intravenous
- 5.4.2. Intracerebroventricular (ICV)
- 5.5. Market Analysis, Insights and Forecast - By End User
- 5.5.1. Hospitals
- 5.5.2. Specialty Clinics
- 5.5.3. Others
- 5.6. Market Analysis, Insights and Forecast - By Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia pacific
- 5.6.4. Rest of the World
6. North America Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Key Findings / Summary
- 6.2. Market Analysis - By Treatment
- 6.2.1. Enzyme Replacement Therapy (ERT)
- 6.2.2. Others
- 6.3. Market Analysis - By Disease Type
- 6.3.1. Mucopolysaccharidosis Type I
- 6.3.2. Mucopolysaccharidosis Type II
- 6.3.3. Mucopolysaccharidosis Type IV A
- 6.3.4. Mucopolysaccharidosis Type VI
- 6.3.5. Others
- 6.4. Market Analysis - By Route of Administration
- 6.4.1. Intravenous
- 6.4.2. Intracerebroventricular (ICV)
- 6.5. Market Analysis - By End User
- 6.5.1. Hospitals
- 6.5.2. Specialty Clinics
- 6.5.3. Others
- 6.6. Market Analysis - By Country
- 6.6.1. U.S.
- 6.6.2. Canada
7. Europe Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Key Findings / Summary
- 7.2. Market Analysis - By Treatment
- 7.2.1. Enzyme Replacement Therapy (ERT)
- 7.2.2. Others
- 7.3. Market Analysis - By Disease Type
- 7.3.1. Mucopolysaccharidosis Type I
- 7.3.2. Mucopolysaccharidosis Type II
- 7.3.3. Mucopolysaccharidosis Type IV A
- 7.3.4. Mucopolysaccharidosis Type VI
- 7.3.5. Others
- 7.4. Market Analysis - By Route of Administration
- 7.4.1. Intravenous
- 7.4.2. Intracerebroventricular (ICV)
- 7.5. Market Analysis - By End User
- 7.5.1. Hospitals
- 7.5.2. Specialty Clinics
- 7.5.3. Others
- 7.6. Market Analysis - By Country/ sub-region
- 7.6.1. U.K.
- 7.6.2. Germany
- 7.6.3. France
- 7.6.4. Spain
- 7.6.5. Italy
- 7.6.6. Rest of Europe
8. Asia Pacific Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Key Findings / Summary
- 8.2. Market Analysis - By Treatment
- 8.2.1. Enzyme Replacement Therapy (ERT)
- 8.2.2. Others
- 8.3. Market Analysis - By Disease Type
- 8.3.1. Mucopolysaccharidosis Type I
- 8.3.2. Mucopolysaccharidosis Type II
- 8.3.3. Mucopolysaccharidosis Type IV A
- 8.3.4. Mucopolysaccharidosis Type VI
- 8.3.5. Others
- 8.4. Market Analysis - By Route of Administration
- 8.4.1. Intravenous
- 8.4.2. Intracerebroventricular (ICV)
- 8.5. Market Analysis - By End User
- 8.5.1. Hospitals
- 8.5.2. Specialty Clinics
- 8.5.3. Others
- 8.6. Market Analysis - By Country/ sub-region
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Rest of Asia Pacific
9. Rest of the World Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Key Findings / Summary
- 9.2. Market Analysis - By Treatment
- 9.2.1. Enzyme Replacement Therapy (ERT)
- 9.2.2. Others
- 9.3. Market Analysis - By Disease Type
- 9.3.1. Mucopolysaccharidosis Type I
- 9.3.2. Mucopolysaccharidosis Type II
- 9.3.3. Mucopolysaccharidosis Type IV A
- 9.3.4. Mucopolysaccharidosis Type VI
- 9.3.5. Others
- 9.4. Market Analysis - By Route of Administration
- 9.4.1. Intravenous
- 9.4.2. Intracerebroventricular (ICV)
- 9.5. Market Analysis - By End User
- 9.5.1. Hospitals
- 9.5.2. Specialty Clinics
- 9.5.3. Others
10. Competitive Analysis
- 10.1. Key Industry Developments
- 10.2. Global Market Share Analysis (2017)
- 10.3. Competition Dashboard
- 10.4. Comparative Analysis - Major Players
- 10.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 10.5.1. Shire (Takeda Pharmaceutical Company Limited)
- 10.5.1.1. Overview,
- 10.5.1.2. Products & services,
- 10.5.1.3. SWOT analysis,
- 10.5.1.4. Recent developments,
- 10.5.1.5. strategies,
- 10.5.1.6. financials (based on availability)
- 10.5.2. Denali Therapeutics
- 10.5.2.1. Overview,
- 10.5.2.2. Products & services,
- 10.5.2.3. SWOT analysis,
- 10.5.2.4. Recent developments,
- 10.5.2.5. strategies,
- 10.5.2.6. financials (based on availability)
- 10.5.3. ArmaGen
- 10.5.3.1. Overview,
- 10.5.3.2. Products & services,
- 10.5.3.3. SWOT analysis,
- 10.5.3.4. Recent developments,
- 10.5.3.5. strategies,
- 10.5.3.6. financials (based on availability)
- 10.5.4. REGENXBIO Inc.
- 10.5.4.1. Overview,
- 10.5.4.2. Products & services,
- 10.5.4.3. SWOT analysis,
- 10.5.4.4. Recent developments,
- 10.5.4.5. strategies,
- 10.5.4.6. financials (based on availability)
- 10.5.5. Sangamo Therapeutics
- 10.5.5.1. Overview,
- 10.5.5.2. Products & services,
- 10.5.5.3. SWOT analysis,
- 10.5.5.4. Recent developments,
- 10.5.5.5. strategies,
- 10.5.5.6. financials (based on availability)
- 10.5.6. BioMarin
- 10.5.6.1. Overview,
- 10.5.6.2. Products & services,
- 10.5.6.3. SWOT analysis,
- 10.5.6.4. Recent developments,
- 10.5.6.5. strategies,
- 10.5.6.6. financials (based on availability)
- 10.5.7. Lysogene
- 10.5.7.1. Overview,
- 10.5.7.2. Products & services,
- 10.5.7.3. SWOT analysis,
- 10.5.7.4. Recent developments,
- 10.5.7.5. strategies,
- 10.5.7.6. financials (based on availability)
- 10.5.8. Abeona Therapeutics Inc.
- 10.5.8.1. Overview,
- 10.5.8.2. Products & services,
- 10.5.8.3. SWOT analysis,
- 10.5.8.4. Recent developments,
- 10.5.8.5. strategies,
- 10.5.8.6. financials (based on availability)
- 10.5.9. Ultragenyx Pharmaceutical
- 10.5.9.1. Overview,
- 10.5.9.2. Products & services,
- 10.5.9.3. SWOT analysis,
- 10.5.9.4. Recent developments,
- 10.5.9.5. strategies,
- 10.5.9.6. financials (based on availability)
- 10.5.10. Genzyme Corporation
- 10.5.10.1. Overview,
- 10.5.10.2. Products & services,
- 10.5.10.3. SWOT analysis,
- 10.5.10.4. Recent developments,
- 10.5.10.5. strategies,
- 10.5.10.6. financials (based on availability)
- 10.5.1. Shire (Takeda Pharmaceutical Company Limited)
11. Competitive Analysis
List of Tables
- Table 1: Global Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 2: Global Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
- Table 3: Global Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 4: Global Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
- Table 5: Global Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
- Table 6: North America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 7: North America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
- Table 8: North America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 9: North America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
- Table 10: North America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
- Table 11: Europe Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 12: Europe Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
- Table 13: Europe Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 14: Europe Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
- Table 15: Europe Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
- Table 16: Asia Pacific Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 17: Asia Pacific Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
- Table 18: Asia Pacific Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 19: Asia Pacific Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
- Table 20: Asia Pacific Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
- Table 21: Latin America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 22: Latin America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
- Table 23: Latin America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 24: Latin America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
- Table 25: Latin America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
- Table 26: Middle East & Africa Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 27: Middle East & Africa Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
- Table 28: Middle East & Africa Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 29: Middle East & Africa Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
- Table 30: Middle East & Africa Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Mucopolysaccharidosis Treatment Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
- Figure 2: Global Mucopolysaccharidosis Treatment Market Value Share (%), by Treatment, 2025 & 2034
- Figure 3: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Enzyme Replacement Therapy (ERT), 2021-2034
- Figure 4: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Others, 2021-2034
- Figure 5: Global Mucopolysaccharidosis Treatment Market Value Share (%), by Disease Type, 2025 & 2034
- Figure 6: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Mucopolysaccharidosis Type I, 2021-2034
- Figure 7: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Mucopolysaccharidosis Type II, 2021-2034
- Figure 8: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Mucopolysaccharidosis Type IV A, 2021-2034
- Figure 9: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Mucopolysaccharidosis Type VI, 2021-2034
- Figure 10: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Others, 2021-2034
- Figure 11: Global Mucopolysaccharidosis Treatment Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 12: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Intravenous, 2021-2034
- Figure 13: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Intracerebroventricular (ICV), 2021-2034
- Figure 14: Global Mucopolysaccharidosis Treatment Market Value Share (%), by End-user, 2025 & 2034
- Figure 15: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Hospitals, 2021-2034
- Figure 16: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Specialty Clinics, 2021-2034
- Figure 17: Global Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Region, 2025 & 2034
- Figure 18: North America Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
- Figure 19: North America Mucopolysaccharidosis Treatment Market Value Share (%), by Treatment, 2025
- Figure 20: North America Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
- Figure 21: North America Mucopolysaccharidosis Treatment Market Value Share (%), by Disease Type, 2025
- Figure 22: North America Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
- Figure 23: North America Mucopolysaccharidosis Treatment Market Value Share (%), by Route of Administration, 2025
- Figure 24: North America Mucopolysaccharidosis Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
- Figure 25: North America Mucopolysaccharidosis Treatment Market Value Share (%), by End-user, 2025
- Figure 26: North America Mucopolysaccharidosis Treatment Market Value (US$ Mn), By Country, 2025 & 2034
- Figure 27: North America Mucopolysaccharidosis Treatment Market Value Share (%), By Country, 2025
- Figure 28: Europe Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
- Figure 29: Europe Mucopolysaccharidosis Treatment Market Value Share (%), by Treatment, 2025
- Figure 30: Europe Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
- Figure 31: Europe Mucopolysaccharidosis Treatment Market Value Share (%), by Disease Type, 2025
- Figure 32: Europe Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
- Figure 33: Europe Mucopolysaccharidosis Treatment Market Value Share (%), by Route of Administration, 2025
- Figure 34: Europe Mucopolysaccharidosis Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
- Figure 35: Europe Mucopolysaccharidosis Treatment Market Value Share (%), by End-user, 2025
- Figure 36: Europe Mucopolysaccharidosis Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
- Figure 37: Europe Mucopolysaccharidosis Treatment Market Value Share (%), By Country/ Sub-region, 2025
- Figure 38: Asia Pacific Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
- Figure 39: Asia Pacific Mucopolysaccharidosis Treatment Market Value Share (%), by Treatment, 2025
- Figure 40: Asia Pacific Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
- Figure 41: Asia Pacific Mucopolysaccharidosis Treatment Market Value Share (%), by Disease Type, 2025
- Figure 42: Asia Pacific Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
- Figure 43: Asia Pacific Mucopolysaccharidosis Treatment Market Value Share (%), by Route of Administration, 2025
- Figure 44: Asia Pacific Mucopolysaccharidosis Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
- Figure 45: Asia Pacific Mucopolysaccharidosis Treatment Market Value Share (%), by End-user, 2025
- Figure 46: Asia Pacific Mucopolysaccharidosis Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
- Figure 47: Asia Pacific Mucopolysaccharidosis Treatment Market Value Share (%), By Country/ Sub-region, 2025
- Figure 48: Latin America Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
- Figure 49: Latin America Mucopolysaccharidosis Treatment Market Value Share (%), by Treatment, 2025
- Figure 50: Latin America Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
- Figure 51: Latin America Mucopolysaccharidosis Treatment Market Value Share (%), by Disease Type, 2025
- Figure 52: Latin America Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
- Figure 53: Latin America Mucopolysaccharidosis Treatment Market Value Share (%), by Route of Administration, 2025
- Figure 54: Latin America Mucopolysaccharidosis Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
- Figure 55: Latin America Mucopolysaccharidosis Treatment Market Value Share (%), by End-user, 2025
- Figure 56: Latin America Mucopolysaccharidosis Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
- Figure 57: Latin America Mucopolysaccharidosis Treatment Market Value Share (%), By Country/ Sub-region, 2025
- Figure 58: Middle East & Africa Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
- Figure 59: Middle East & Africa Mucopolysaccharidosis Treatment Market Value Share (%), by Treatment, 2025
- Figure 60: Middle East & Africa Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
- Figure 61: Middle East & Africa Mucopolysaccharidosis Treatment Market Value Share (%), by Disease Type, 2025
- Figure 62: Middle East & Africa Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
- Figure 63: Middle East & Africa Mucopolysaccharidosis Treatment Market Value Share (%), by Route of Administration, 2025
- Figure 64: Middle East & Africa Mucopolysaccharidosis Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
- Figure 65: Middle East & Africa Mucopolysaccharidosis Treatment Market Value Share (%), by End-user, 2025
- Figure 66: Middle East & Africa Mucopolysaccharidosis Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
- Figure 67: Middle East & Africa Mucopolysaccharidosis Treatment Market Value Share (%), By Country/ Sub-region, 2025
- Figure 68: Global Mucopolysaccharidosis Treatment Market Share (%), By Company, 2025
